Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of January 3, 2025 • 1:41 PM ET

Date/Time Source News Release
01/02/2025 08:00 AM EST GlobeNewswire Lexicon Appoints Scott Coiante as Chief Financial Officer
12/20/2024 04:30 PM EST GlobeNewswire Lexicon Announces Receipt of Complete Response Letter for Zynquista(TM) (sotagliflozin)
11/26/2024 08:00 AM EST GlobeNewswire Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
11/25/2024 04:15 PM EST GlobeNewswire Lexicon Pharmaceuticals to Participate in December Investor Conferences
11/22/2024 07:32 AM EST GlobeNewswire Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA
11/20/2024 04:05 PM EST GlobeNewswire Lexicon Appoints Ivan H. Cheung to Board of Directors
09/27/2024 08:00 AM EDT GlobeNewswire Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress
09/16/2024 08:00 AM EDT GlobeNewswire Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer
09/10/2024 08:00 AM EDT GlobeNewswire New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes
09/03/2024 04:00 PM EDT GlobeNewswire Lexicon Pharmaceuticals to Participate in Upcoming September Investor Conferences
Page

Additional News

As of January 3, 2025 • 1:41 PM ET

Date/Time Source News Release
Page